How semaglutide affects heart and muscle mass
Part of Hormones & metabolism clinical trials.
This study looks at how semaglutide (Ozempic or Wegovy) changes heart muscle and body muscle. It may help people with type 2 diabetes or those taking the drug for weight loss understand if their heart is affected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You are about to start taking semaglutide for type 2 diabetes or to lose weight
- You have not taken semaglutide for more than 2 weeks yet
- You can safely have an MRI (no metal implants, pacemaker, or severe claustrophobia)
- You can walk without help (no cane, walker, or wheelchair)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses MRI scans to look at how the diabetes medication semaglutide affects body composition in people with type 2 diabetes and obesity. It may help doctors understand how this treatment works in the body.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This study tests whether semaglutide (a weight-loss medication) works differently in people with varying degrees of insulin resistance (how well your body uses sugar). If you are obese without diabetes, you may be able to join.
This trial studies whether the drug semaglutide can help people with heart failure who are overweight. It aims to see if the drug improves heart function and symptoms.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.